Cargando…

Paclitaxel-Fe(3)O(4) nanoparticles inhibit growth of CD138(−) CD34(−) tumor stem-like cells in multiple myeloma-bearing mice

BACKGROUND: There is growing evidence that CD138(−) CD34(−) cells may actually be tumor stem cells responsible for initiation and relapse of multiple myeloma. However, effective drugs targeted at CD138(−) CD34(−) tumor stem cells are yet to be developed. The purpose of this study was to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Cuiping, Wang, Jing, Chen, Dengyu, Chen, Junsong, Xiong, Fei, Zhang, Hongyi, Zhang, Yunxia, Gu, Ning, Dou, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629869/ https://www.ncbi.nlm.nih.gov/pubmed/23610522 http://dx.doi.org/10.2147/IJN.S38447

Ejemplares similares

Evaluation of characteristics of CD44(+)CD117(+) ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures
por: Chen, Junsong, et al.
Publicado: (2013)

MicroRNA-200c overexpression inhibits tumorigenicity and metastasis of CD117(+)CD44(+) ovarian cancer stem cells by regulating epithelial-mesenchymal transition
por: Chen, Dengyu, et al.
Publicado: (2013)

Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138(++) and CD138(low) Subpopulations in Multiple Myeloma Cell Lines
por: Paíno, Teresa, et al.
Publicado: (2014)

In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma
por: Omstead, David T., et al.
Publicado: (2020)

Isolation of Human CD138(+) Microparticles from the Plasma of Patients with Multiple Myeloma()
por: Krishnan, Sabna Rajeev, et al.
Publicado: (2016)

Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells
por: Jeong, Tae-Dong, et al.
Publicado: (2012)

Cardiovascular Involvement of a CD138-Negative Anaplastic Myeloma: A Diagnostic Dilemma
por: Choudhuri, Jui, et al.
Publicado: (2023)

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
por: Sun, Chuang, et al.
Publicado: (2019)

Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma
por: Soloveva, Maiia, et al.
Publicado: (2023)

Role of CD138, CD56, and light chain immunohistochemistry in suspected and diagnosed plasma cell myeloma: A prospective study
por: Dass, Jasmita, et al.
Publicado: (2019)

CD138(-) multiple myeloma cells express high level of CHK1 which correlated to overall survival in MM patient
por: Wu, Dong, et al.
Publicado: (2020)

Soluble syndecan-1 (CD138): is it useful as a prognostic factor in Korean patients with multiple myeloma?
por: Lee, Je-Jung
Publicado: (2010)

Syndecan-1 (CD138), Carcinomas and EMT
por: Couchman, John R.
Publicado: (2021)

Expression analysis of multiple myeloma CD138 negative progenitor cells using single molecule microarray readout
por: Jacak, Jaroslaw, et al.
Publicado: (2013)

Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
por: KAWANO, YAWARA, et al.
Publicado: (2012)

Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells
por: KAWANO, YAWARA, et al.
Publicado: (2013)

Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells
por: Kishimoto, Renata Kiyomi, et al.
Publicado: (2016)

Comment on: “Validation of interphase fluorescence in situ hybridization (iFISH) of CD138 positive cells in multiple myeloma”()
por: Zalcberg Renault, Ilana
Publicado: (2016)

Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma
por: Cengiz, Arzu, et al.
Publicado: (2018)

Gene therapy of ovarian cancer using IL-21-secreting human umbilical cord mesenchymal stem cells in nude mice
por: Zhang, Yunxia, et al.
Publicado: (2014)

An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/lambda ratios of CD38-gated CD138(+) cells
por: Nakayama, Shoko, et al.
Publicado: (2012)

A Multiepitope of XBP1, CD138 and CS1 Peptides Induces Myeloma-Specific Cytotoxic T lymphocytes in T cells of Smoldering Myeloma Patients
por: Bae, Jooeun, et al.
Publicado: (2014)

Comparison of the IHC Markers CD138 and CD43 in Oral Leukoplakia: An Original Research
por: Akkaloori, Anitha, et al.
Publicado: (2023)

Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device
por: Qasaimeh, Mohammad A., et al.
Publicado: (2017)

CD10 and CD138 can be expressed in giant cell tumor of bone: An immunohistochemical study
por: Al-Abbadi, Mousa A., et al.
Publicado: (2016)

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility
por: Misiewicz-Krzeminska, Irena, et al.
Publicado: (2018)

miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma
por: Papadimitriou, Maria-Alexandra, et al.
Publicado: (2023)

High expression of nucleoporin 133 mRNA in bone marrow CD138+ cells is a poor prognostic factor in multiple myeloma
por: Ibata, Soushi, et al.
Publicado: (2018)

Junctional adhesion molecule C expression specifies a CD138(low/neg) multiple myeloma cell population in mice and humans
por: Brandl, Andreas, et al.
Publicado: (2022)

Investigation of the Relationship between Chronic Endometritis Manifestations under Hysteroscope and CD138 Expression
por: Wang, Shuang, et al.
Publicado: (2022)

Beyond Uterine Natural Killer Cell Numbers in Unexplained Recurrent Pregnancy Loss: Combined Analysis of CD45, CD56, CD16, CD57, and CD138
por: Chiokadze, Maia, et al.
Publicado: (2020)

Study on expression of plasma sCD138 in patients with hemorrhagic fever with renal syndrome
por: Li, Jing, et al.
Publicado: (2018)

PB2077: COMPARISON OF PLASMA CELL PERCENTAGE BY BONE MARROW ASPIRATE MORPHOLOGY AND CD138-STAINED BONE MARROW BIOPSY IN SMOLDERING MYELOMA TO PREDICT TRANSFORMATION TO SYMPTOMATIC MYELOMA
por: Cashman, Helen, et al.
Publicado: (2023)

Differential number of CD34+, CD133+ and CD34+/CD133+ cells in peripheral blood of patients with congestive heart failure
por: Fritzenwanger, M, et al.
Publicado: (2009)

Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins
por: Jung, O, et al.
Publicado: (2016)

Expression of CD81 and CD117 in plasma cell myeloma and the relationship to prognosis
por: Chen, Fang, et al.
Publicado: (2018)

Flow Cytometry Assessment of In Vitro Generated CD138(+) Human Plasma Cells
por: Itoua Maïga, Rayelle, et al.
Publicado: (2014)

MicroRNA-138 suppresses glioblastoma proliferation through downregulation of CD44
por: Yeh, Margaret, et al.
Publicado: (2021)

Glucocorticoid prevents CD138 expression in T cells of autoimmune MRL/lpr mice
por: Xie, Tianhong, et al.
Publicado: (2022)

The Intensity and Pattern of Syndecan-1 (CD138) Expression in Normal and Diseased Livers
por: Atique, Muhammad, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_607nu5hdgtbic5v52ae8lkhtrk